N Context.-Proper diagnosis and therapy of fibrinogen deficiency requires high-quality fibrinogen assays.
time-based reagents compared to Clauss (P , .001), and coefficient of variation was 46% lower for mechanical endpoint instruments compared to photo-optical. Most testing events (97.4%) could be reliably graded as pass or fail using a target range of 620% from the method mean (total pass rate, 98.8%). Total fail rate was 3.0-fold lower for mechanical instruments compared to photo-optical (0.5% versus 1.5%, P = .001). Nonetheless many photo-optical methods had very high precision and very low fail rates.
Conclusions.-Fibrinogen assays showed highly variable methodology and performance characteristics. Bias, precision, and grading were affected by the type of reagent or instrument used.
(Arch Pathol Lab Med. 2012;136:789-795; doi: 10.5858/ arpa.2011-0322-OA) F ibrinogen deficiency is an important risk factor for bleeding, [1] [2] [3] and can be acquired or inherited. Acquired deficiency is most common and causes include disseminated intravascular coagulation, 4 liver disease, 5 hemodilution, 6 and acquired dysfibrinogenemia. 7 Inherited deficiency is caused by mutations of the fibrinogen Aa, Bb, or g gene that result in quantitative or qualitative defects. 8 Fibrinogen activity levels are important in the diagnosis or management of these conditions, particularly in guiding transfusion therapy with cryoprecipitate or fibrinogen concentrate. 2, 3, 9 The first goal of this study was to determine the interlaboratory bias and precision of contemporary fibrinogen activity assays used by a large number of laboratories, and to correlate these parameters with assay variables (reagent type, instrument type, reagent/instrument type). The second goal was to grade the performance of individual laboratories as pass or fail using methodspecific peer group data, and to correlate grading with bias, precision, and assay variables. This was done using external quality assurance data obtained from participants of the 2008 College of American Pathologists proficiency testing program in coagulation.
METHODS

Proficiency Testing Specimens
Two identical vials of normal plasma named CGL-07 and CGL-09 were mailed to more than 3500 participants of the College of American Pathologists proficiency testing program in coagulation in 2008 (2008-CGL-B survey). These plasmas were obtained from a commercial vendor, prepared by pooling plasmapheresis collections obtained from normal donors, aliquoted into 1.0-mL vials, and lyophilized. The laboratory was instructed to reconstitute the plasma by the addition of 1.0 mL of water. Participants were blinded to the identity of the plasmas.
Fibrinogen Assays
Each participating laboratory was asked to perform fibrinogen activity assays according to its local method and to report the assayed values and method used to the College of American Pathologists. A method was defined as a specific reagent and a specific instrument that were combined to create a fibrinogen assay. Each method was classified according to reagent type, instrument type, and reagent/instrument type. There were 2 reagent types (Clauss-based and prothrombin time [PT]-based), 2 instrument types (mechanical endpoint and photo-optical endpoint), and 3 reagent/instrument types (Clauss/mechanical, Clauss/photo-optical, PT-based/photo-optical). Each method was also classified according to peer group size. There were 2 peer group sizes, including a large peer group (if data were reported for 10 or more laboratories) and a small peer group (if data were reported for fewer than 10 laboratories).
Determination of Interlaboratory Bias and Precision of Fibrinogen Assays
All fibrinogen values were assigned to 5 different stratification groups as defined in ''Fibrinogen Assays'': method, reagent type, instrument type, reagent/instrument type, and peer group size. Summary statistics were calculated for each stratification group, including number of laboratories, mean, and coefficient of variation (CV). Outliers were defined as values that exceeded 3 standard deviations from the mean of each stratification group. The mean 6 3 SD was recalculated after this initial outlier exclusion for no more than 2 iterations to exclude any remaining outliers. The final data set, after all outliers were excluded, was used to calculate the final mean and CV. For instrument type and reagent/instrument type calculations, the AMAX 190, 200, and 400 instruments (Trinity Biotech, Bray, Ireland) were excluded from analysis because it was uncertain if participants were reporting fibrinogen values using the mechanical or photo-optical endpoint mode of operation.
Method-specific bias was calculated by comparing the method-specific mean to the all-method mean. The allmethod mean was calculated by taking the average of the method-specific means. The all-method bias was calculated by taking the average of the method-specific biases. The all-method CV was calculated by taking the average of the method-specific CVs.
Test bias was classified into 1 of 3 categories based on the magnitude of the method-specific bias (low bias, bias #5%; intermediate bias, bias 6%-10%; high bias, bias .10%). Test precision was classified into 1 of 4 categories based on the magnitude of the method-specific CV (low precision, CV .20%; intermediate precision, CV 11%-20%; high precision, CV 6%-10%; very high precision, CV #5%).
Grading of Laboratory Performance
Participant results were graded as pass or fail based on the result falling inside (pass) or outside (fail) the 620% target range from the method-specific mean (after outlier exclusion). Only those methods that had 10 or more participant results (ie, large peer groups) were considered valid for estimating a reliable peer group mean; therefore only those methods were graded. 10 
Statistical Analysis
Differences between 2 independent means were tested for significance using the 2-tailed t test. Differences between 2 proportions were tested for significance by calculation of z scores. Linear correlation coefficients were tested for significance using analysis of variance. Values of P , .05 were considered significant.
RESULTS
Fibrinogen Assays
Study participants used 18 different reagents supplied by 5 manufacturers (Table 1) . These were classified into Clauss-based (n 5 9) and PT-based (n 5 9) reagent types. Participants used 20 different instruments supplied by 5 manufacturers (Table 2 ). These were classified into me- chanical endpoint (n 5 5) and photo-optical endpoint (n 5 14) instrument types. One instrument was capable of both mechanical and photo-optical endpoint modes depending on user discretion. There were a total of 50 distinct fibrinogen methods based on various combinations of reagent and instrument (Table 3) .
Bias of Fibrinogen Assays Method-specific bias was highly variable, ranging from 0.0% to 27.0%, with an all-method bias of 8.3% (Table 3) . Method-specific means were highly reproducible between the 2 identical plasmas CGL-07 and CGL-09; the average percentage deviation in method-specific mean was 1.5% (range 0.03%-5.7%). A sizeable number of methods (28%-32%) and laboratories (43.7%-44.1%) were classified as having high bias (bias .10%) ( Table 4) .
Reagent type had the greatest effect on bias. PT-based reagents had 11.7% higher fibrinogen values than Claussbased reagents after controlling for reagent/instrument type (Table 5) .
Instrument type had a small effect on bias. Photo-optical endpoint instruments had 2.8% lower fibrinogen levels than mechanical endpoint instruments after controlling for reagent/instrument type (Table 5 ). Although this effect was statistically significant, it was not considered clinically significant.
Peer group size did not have a consistently significant effect on bias.
Precision of Fibrinogen Assays
Method-specific precision was highly variable, with CVs ranging from 0.7% to 25.8% and an all-method CV of 7.7% (Table 3) . Most methods (82%-88%) and laboratories (98.0%-98.9%) were classified as having high precision or better (CV #10%), and some methods (26%-30%) and laboratories (11.7%-13.4%) had very high precision (CV #5%) (Table 4) .
Instrument type had the greatest effect on precision. Mechanical endpoint instruments had on average 46% lower CV (higher precision) than photo-optical endpoint instruments after controlling for reagent/ instrument type (Table 5) . Although most photo-optical instruments showed overall lower precision, there were a few with precision similar to mechanical endpoint instruments.
Peer group size had a small effect on precision. Large peer groups had 24% lower CV than small peer groups.
Reagent type had the smallest effect on precision. Clauss-based reagents had 10% lower CV than PTbased reagents after controlling for reagent/instrument type.
Grading of Fibrinogen Assays
Most laboratories (n 5 3513-3515; 97.4%) used methods that were classified into large peer groups (n 5 29 methods; 58%) ( Table 6 ). Among these gradable laboratories, 98.7% to 98.9% received passing grades using a target range of 620% from the method-specific mean. A very low proportion of laboratories (2.6%) couldn't be graded using this grading scheme because they fell into small peer groups; however, these groups represented a sizeable number of fibrinogen methods (n 5 21 methods; 42%).
Method-specific failure rates were variable, ranging from 0.0% to 12.5%. Failure rates were significantly affected by instrument type. Mechanical endpoint instruments gave 2.5-to 3.6-fold lower failure rates than photooptical endpoint instruments (Table 7) . If the grades for specimens CGL-07 and CGL-09 were combined, then the overall failure rate was 3.0-fold lower for mechanical instruments compared to photo-optical (P 5 .001). Many methods using photo-optical instruments had very low fail rates (n 5 12-13 methods with fail rate of 0.0%) despite the overall higher fail rate for this instrument type. Failure rates were not significantly affected by reagent type.
There was a significant linear correlation between failure rate and method-specific CV (for CGL-07, r 2 5 0.343, P , .001; for CGL-09, r 2 5 0.440, P , .001). This suggested that the lower failure rate of mechanical endpoint instruments was due to their higher precision. There was a lower and inconsistent linear correlation between failure rate and bias (for CGL-07, r 2 5 0.107, P 5 .08; for CGL-09, r 2 5 0.152, P 5 .04). COMMENT Fibrinogen assays play an important role in the evaluation of bleeding patients. Very low levels of fibrinogen are associated with an increased risk of bleeding often requiring treatment with cryoprecipitate or other fibrinogen concentrates. [1] [2] [3] 9 It is therefore critical to have a reliable fibrinogen assay.
Two kinds of errors could lead to falsely decreased or falsely elevated fibrinogen results and consequently to overtreatment or undertreatment. The first kind of error is imprecision (high CV), which may randomly produce clinically significant errors. Although our study did not assess what level of imprecision is clinically unacceptable, only one reagent-instrument combination had a CV .20% (Table 3) , which we estimated may be a clinically unacceptable level of imprecision.
The second type of error is inaccuracy (high bias), which may produce clinically significant errors even if the assay is precise. Prothrombin time-based fibrinogen assays can generate falsely high fibrinogen results depending on the type of thromboplastin used and the patient's underlying condition. 11, 12 For example, PT-based assays can overestimate fibrinogen results in patients with and without dysfibrinogenemia, 13, 14 and can disagree with Clauss-based assays in patients with low fibrinogen. 13, 15 One study even concluded that some PT-based fibrinogen assays were clinically unsafe.
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Our results supported these findings. Although our study did not assess what level of bias is unacceptable for clinical use, we estimated that .20% bias may be clinically unacceptable. Five reagent-instrument combinations had .20% bias, and all 5 involved PT-based reagents (Table 3) . Laboratory directors are cautioned to carefully evaluate the combination of reagent and instrument, along with the intended use of the assay, before selecting a fibrinogen assay. Although some PT-based assays with high bias may be acceptable for research applications, they should probably not be used clinically.
In addition to the above conclusions about the appropriateness of specific reagent-instrument combinations, we can also draw some general conclusions about contemporary fibrinogen assays. First, there were a high number of fibrinogen methods used by clinical laboratories. This was due to a competitive marketplace (ie, 5 reagent kit manufacturers) and multiple reagent/instrument combinations (ie, Clauss versus PT-based reagents, and mechanical versus photo-optical instruments).
Second, there was wide disparity in bias and precision among fibrinogen methods. This was consistent with College of American Pathologists data published 20 years ago showing method-specific biases as high as 77 mg/dL on normal plasma and method-specific CVs ranging from 7.4% to 21.6%. 16, 17 Bias was still high for some methods in the current study, up to 27%, which was equivalent to about 80 mg/dL. Other external quality assurance organizations also observe high interlaboratory bias, and some groups suggest that this can be reduced by using a common fibrinogen calibrator, although this is controversial. [18] [19] [20] Precision was improved in our study, as shown by some methods and laboratories with very high precision (CV #5%).
Third, bias and precision were differentially affected by reagent and instrument type. PT-based reagents gave higher fibrinogen levels, suggesting that the mechanism of fibrin clot generation (direct addition of thromboplastin versus thrombin) was an important source of systematic error. Mechanical endpoint instruments gave (on average) higher precision, implying that random error was dependant on fibrin clot properties. Mechanical properties such as clot tensile strength may have greater reproducibility than photo-optical properties such as clot turbidity or light scattering. The observation that some photo-optical instruments had very high precision indicated that this technology could also be optimized for high performance.
Fourth, the performance of laboratories could be graded using method-specific peer group data. The high overall pass rate suggested that local laboratories were applying good quality control practices. The dependence of fail rate on method precision may have implications for laboratories experiencing high fail rates on proficiency testing. For example, a laboratory may be able to decrease its fail rate by using a higher-precision method. Reagent kit vendors can play a role in this process by assisting laboratories in choosing methods with optimal performance characteristics (high precision and low bias) and adequate peer group size for grading.
One limitation of our study was that we did not assess test performance at fibrinogen concentrations near the clinical decision threshold of 100 mg/dL. 2, 3 Although the preparation of a hypofibrinogenemic plasma specimen in multi-liter quantities would be technically challenging, this type of study should be encouraged. Our study of normal plasma should provide a foundation for interpreting results obtained on abnormal plasma.
In summary, fibrinogen assays showed highly variable performance characteristics. Bias, precision, and grading were differentially affected by reagent and instrument type. These variables should be considered in the selection process for a clinical fibrinogen assay.
